GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum Genomics (OTCPK:QNNTF) » Definitions » Institutional Ownership

Quantum Genomics (Quantum Genomics) Institutional Ownership : 0.46% (As of Apr. 30, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Quantum Genomics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Quantum Genomics's institutional ownership is 0.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Quantum Genomics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Quantum Genomics's Float Percentage Of Total Shares Outstanding is 0.00%.


Quantum Genomics Institutional Ownership Historical Data

The historical data trend for Quantum Genomics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum Genomics Institutional Ownership Chart

Quantum Genomics Historical Data

The historical data trend for Quantum Genomics can be seen below:

2022-12-31 2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30
Institutional Ownership 1.15 1.21 0.68 0.68 0.46 0.46 0.46 0.46 0.46 0.46

Quantum Genomics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Quantum Genomics (Quantum Genomics) Business Description

Traded in Other Exchanges
Address
33, Rue Marbeuf, Paris, FRA, 75008
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.